Artivion, Inc. (NYSE:AORT) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analyst sentiment is moderately bullish: Seven brokerages give Artivion an average “Moderate Buy” rating, with six buys and one sell. The average 12-month price target is $44.83.
• Artivion reported quarterly earnings of $0.13 per share and revenue of $125.76 million, exceeding analysts’ $119.99 million forecast, though it posted a slightly negative net margin.
• The stock opened at $21.40, well below its 52-week high of $48.25. Insiders sold 90,460 shares worth $2.56 million in the last quarter, while institutional investors own 86.37% of the company.

Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) have earned an average rating of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $44.83.

Several research analysts have commented on the stock. Canaccord Genuity Group increased their price objective on shares of Artivion from $39.00 to $40.00 and gave the company a "buy" rating in a report on Tuesday, August 18th. Citigroup restated a "market outperform" rating on shares of Artivion in a research report on Tuesday, July 21st. Weiss Ratings cut Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Needham & Company LLC reiterated a "buy" rating and issued a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Finally, Wall Street Zen downgraded Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th.

Artivion Price Performance

AORT stock opened at $21.40 on Wednesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company's fifty day moving average price is $25.18 and its 200-day moving average price is $26.57. Artivion has a one year low of $19.16 and a one year high of $48.25. The company has a market capitalization of $1.04 billion, a PE ratio of -305.63 and a beta of 1.23.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million during the quarter, compared to analysts' expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, equities analysts anticipate that Artivion will post 0.45 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean Holloway sold 977 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the transaction, the senior vice president owned 184,118 shares in the company, valued at $5,245,521.82. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Andrew Green sold 11,480 shares of Artivion stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the sale, the senior vice president directly owned 40,160 shares in the company, valued at approximately $1,002,795.20. The trade was a 22.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 90,460 shares of company stock worth $2,557,366 in the last quarter. 6.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. lifted its stake in shares of Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after purchasing an additional 399 shares during the last quarter. Versant Capital Management Inc increased its position in shares of Artivion by 38.0% during the 3rd quarter. Versant Capital Management Inc now owns 2,119 shares of the company's stock valued at $48,000 after purchasing an additional 584 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Artivion during the 2nd quarter valued at approximately $103,000. Pictet Asset Management Holding SA raised its holdings in Artivion by 25.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,520 shares of the company's stock valued at $202,000 after buying an additional 1,125 shares during the period. Finally, Commerce Bank purchased a new stake in Artivion during the 2nd quarter valued at $208,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc NYSE: AORT is a medical device company focused on products and services for cardiac and vascular surgery. The company develops, manufactures and distributes implantable devices, surgical adhesives and preserved human tissues used in the treatment of complex cardiovascular conditions.

Its product portfolio includes On-X mechanical heart valves and related repair technologies, BioGlue surgical adhesive, aortic stent grafts and other devices for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in surgical procedures.

The company was formerly known as CryoLife, Inc and adopted the Artivion name in 2021 to reflect its broader focus on cardiovascular and aortic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.